Atıf İçin Kopyala
AYGEN B., DEMİRTÜRK N., YILDIZ O., ÇELEN M. K., Celik I., Barut S., ...Daha Fazla
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, sa.4, ss.305-317, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
31
Sayı:
4
-
Basım Tarihi:
2020
-
Doi Numarası:
10.5152/tjg.2020.19197
-
Dergi Adı:
TURKISH JOURNAL OF GASTROENTEROLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.305-317
-
Anahtar Kelimeler:
Chronic hepatitis C, HCV genotypes 1 and 4, ombitasvir, paritaprevir, dasabuvir, real-world effectiveness, SUSTAINED VIROLOGICAL RESPONSE, RITONAVIR PLUS RIBAVIRIN, ANTIVIRAL THERAPY, HCV, OMBITASVIR, PARITAPREVIR, ABT-450/R-OMBITASVIR, MULTICENTER, PARITAPREVIR/RITONAVIR/OMBITASVIR, RETREATMENT
-
Erciyes Üniversitesi Adresli:
Evet
Özet
Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice.